The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.
Search or browse funded studies
Previously funded studies appear chronologically, with the most recent appearing first.
-
Defining Cognitive Phenotypes of Parkinson’s Disease, 2011The Relationship Between Cognitive Phenotypes of PD with Visual Hallucinations and 5HT2A Receptors in the Inferotemporal Cortex
Objective/Rationale:
The project aims to understand the mechanisms underlying cognitive deficits that are associated with visual hallucinations (VH) in Parkinson’s disease (PD). We have previously... -
Therapeutic Pipeline Program, 2015Improving Access to Depression Care in Parkinson’s Disease: A Telehealth Approach
Study Rationale:
There is a critical need for treatments that address depression and barriers to care among the approximately 5 million people living with Parkinson’s disease (PD)... -
Repositioning Drugs for PD, 2011Evaluation of a Specific DAT Inhibitor in Pre-clinical Models of Parkinson's Disease
Objective/Rationale:
MLR-1017 is a psychostimulant drug used clinically for a variety of neuropsychiatric and other applications, but has never been tested in Parkinson’s disease (PD). Levodopa is a... -
Target Validation, 2011Pathway Validation of a Biased Delta Opioid Receptor Ligand for PD Symptoms & Side Effects Relief
Objective/Rationale:
Endogenous activation of the Delta opioid receptor (DOR) serves as a compensatory mechanism to alleviate Parkinson’s disease (PD) symptoms. However, DOR-mediated convulsions have... -
Rapid Response Innovation Awards, 2014Levodopa Versus Dopamine Agonist after Deep Brain Stimulation in Parkinson's Disease
Study Rationale:
Deep brain stimulation (DBS) of the subthalamic nucleus (STN) is an established treatment for patients with advanced Parkinson's disease (PD). STN DBS improves motor... -
Repositioning Drugs for PD, 2011Duloxetine Hydrochloride as a Novel Neuroprotective Treatment for Parkinson's Disease
Objective/Rationale:
In Parkinson’s disease (PD) dopaminergic neurons in the midbrain region substantia nigra pars compacta die. There is currently no treatment available that prevents this cell death...
Apply for a Grant
Our funding programs support basic, translational and clinical research from academia and industry.